Loading market dashboard
Poxel S.A.
PXXLFHealthcareOTCFR
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
LYON, France--(BUSINESS WIRE)--Regulatory News: Poxel (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for severe chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today announced its revenue for the first quarter ended March 31, 2026, and provided a business update. Commercial and Clinical Activity Update TWYMEEG® (Imeglimin) For the quarter.
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company that leverages its expertise to develop innovative treatments for metabolic diseases, including certain rare diseases (the “Company”), announces the postponement of the publication of its annual financial statements for the fiscal year ended December 31, 2025, and its 2025 annual financial report. This decision is related to the completion, since the Lyon Commercial Court appro.
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and certain rare diseases, today announced that it has entered into a definitive agreement with SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company A U.S. pharmaceutical company specializing in the deve.
LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases (the "Company"), announces that it has signed, on March 25, 2026, the new Tranche D PDR subscription agreement with IPF Partners ("IPF"), for €3.75 million as part of th.
